FGFR3 and transitional cell carcinoma: We further demonstrate a role for TAK1 as a positive regulator of NFκB activity downstream of FGFR3 in both multiple myeloma and urothelial cell carcinoma, two cancers with demonstrated FGFR3 involvement [10], [31], with modulatory effects on cell adhesion.